Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | Remaining barriers to the translation of EV-based therapies

Eva Rohde • 10 Jun 2021

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, considers some of the major bottlenecks that need to be addressed in order to drive the translation of extracellular vesicle-derived therapeutics to the clinic. She highlights the importance of collecting comparable preclinical data, the thorough preclinical characterization of EVs and secreted factors, as well an early focus on Chemistry, Manufacturing, and Control (CMC) processes. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.


Eva Rohde is CEO of PMU Innovations GmbH., Salzburg, Austria. Eva Rohde is a Medical Consultant of MDimune Inc., Seoul, Korea.